About ViroDyn
A small, founder-led gene therapeutics company out of the UK. We design gene-level corrections that target the cause of monogenic disease, not its symptoms.
We use computational disease modelling to identify high-leverage gene-level corrections for monogenic diseases. Each programme starts from human genetic evidence, builds a scored model, and designs a correction at the highest-leverage point.
Our lead programme is in Crohn's disease. The pipeline expands as each target clears its prespecified validation tests. See Approach for the methodology and Programmes for what we're building.
Two founders. Four scientific advisors. One programme deep, several more prioritised.
Leads the science. Master's in genetics from Sussex and first author of the Crohn's disease preprint on Zenodo. Runs target discovery, computational disease modelling, and each programme end-to-end.
Runs operations and strategy. Bachelor's in genetics from Sussex; master's in genetics & development with bioinformatics in progress. Leads funding research, direction-setting, and scientific audits across all programmes.
Supported by four scientific advisors: professors in genetics, oncology, gene therapy, and bioinformatics, who also connect us to industry leadership and funding networks. Names disclosed to aligned investors under NDA.
We have a published disease model, a scored target set, and prespecified validation criteria for our lead Crohn's disease programme. The computational work is done. The next step is a cell-line proof of concept: testing our highest-leverage corrections in disease-relevant cell models against the pass/fail criteria we have already defined. That work is funding-dependent, and we are actively seeking a pre-seed round to cross the gate.